Neumora

Pre-Approval PRO BETA

🟡

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 7/9/2024

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Major Depressive Disorder Major Depressive Episode Associated With Bipolar II Disorder Alzheimer's Disease Healthy Elderly

NCT06029439 Phase 3 RECRUITING

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Started: 11/10/2023

NCT06058039 Phase 3 ACTIVE NOT RECRUITING

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Started: 12/21/2023

NCT06058013 Phase 3 ACTIVE NOT RECRUITING

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Started: 12/20/2023

NCT06029426 Phase 3 COMPLETED

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Started: 9/20/2023

NCT06429722 Phase 2 COMPLETED

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Started: 5/13/2024

NCT04221230 Phase 2 COMPLETED

Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

Started: 1/3/2020

NCT06546995 Phase 1 COMPLETED

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Started: 7/9/2024

NMRA-335140 Placebo NMRA-335140 80 mg NMRA-323511

Activity Status: Slowing

Last Trial Started: 7/9/2024

Last Trial Ended: 11/19/2025

Trials (12 months): 0

Completed Trials: 4

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.